Viking Therapeutics, Inc. - Common Stock (VKTX)

Viking Therapeutics (NASDAQ:VKTX) reported a wider second-quarter loss as the company increased spending to advance its obesity pipeline, including its lead dual GLP-1/GIP receptor agonist, VK2735, through Phase III development in injectable and planned oral formulations. The company reported a net

The stock looks like a high-risk, high-reward play.

Viking's latest program seeks to push the envelope in weight loss efficacy.

Wall Street analysts are highly bullish on Viking Therapeutics, not least because of its promising weight-loss drug, with ongoing and upcoming phase 3 trials.

Investors need to ask tough questions before initiating a position in this biotech company.

There are good reasons to invest in Lilly and to hold off.

Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 10 years by 26.85% on an annualized basis producing an average annual return of 40.15%. Currently, Viking Therapeutics has a market

This biotech has a powerful growth story, but one competitive threat could reshape the entire investment case before the payoff arrives.

The stock has soared 400% in recent years.

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

The stock is known to soar on good news.

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

That would be an impressive run if it could get there soon.

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare.

The GLP-1 drug market is massive and still growing fast. Investing in a promising growth stock in the space could lead to significant returns.

The drugmaker is looking to challenge the leaders in the weight loss market.

Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.

Shoppers keep coming back to these companies.

Viking stock is known for soaring after positive news.

If you look beyond the upside potential, there's still plenty of risk to navigate past.